PTC
BCAX

Private Trust Company’s Bicara Therapeutics BCAX Stock Holding History

Private Trust Company’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.68K Hold
225
– – ﹤0.01% 2214
2026
Q1 		$4.47K Hold
225
– – ﹤0.01% 2222
2025
Q4 		$3.79K Hold
225
– – ﹤0.01% 2235
2025
Q3 		$3.55K Buy
+225
New +$2.52K ﹤0.01% 2234

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Private Trust Company's BCAX Position: Q2 2026 in Review

Private Trust Company held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 225 shares worth $6.68K. The position accounts for ﹤0.01% of the portfolio, ranked #2214.

Private Trust Company first reported a position in BCAX in Q3 2025 and has held it in 4 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Private Trust Company held 225 shares of Bicara Therapeutics worth $6.68K as of Q2 2026.
  • Private Trust Company left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #2214 holding.
  • Private Trust Company first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.